© Drug Hunter Inc. 2018-2023
Home > linrodostat
oral sel. IDO1 dioxygenase inhibitor
100 mg QD, in I/O combo studies for cancer
acts on apo-IDO1 displacing heme co-factor
Mol. Cancer Ther., Dec. 9, 2020
BMS, Princeton, NJ / Flexus, San Carlos, CA
Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year